Last reviewed · How we verify
Talineuren
Talineuren is a Small molecule drug developed by InnoMedica Schweiz AG. It is currently in Phase 2 development. Also known as: TLN, Liposomal GM1, liposomal GM1.
Talineuren is being studied as a potential treatment for Parkinson Disease in a clinical trial. The trial, titled "Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease," is comparing the efficacy of Talineuren to a placebo in patients with Parkinson Disease.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Talineuren |
|---|---|
| Also known as | TLN, Liposomal GM1, liposomal GM1 |
| Sponsor | InnoMedica Schweiz AG |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease (PHASE2)
- Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Talineuren CI brief — competitive landscape report
- Talineuren updates RSS · CI watch RSS
- InnoMedica Schweiz AG portfolio CI
Frequently asked questions about Talineuren
What is Talineuren?
Who makes Talineuren?
Is Talineuren also known as anything else?
What development phase is Talineuren in?
Related
- Manufacturer: InnoMedica Schweiz AG — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: TLN, Liposomal GM1, liposomal GM1
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing